Angel Broking neutral on Sun Pharma

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Angel Broking`s research report on Sun Pharmaceutical Industries“For 1QFY2015, Sun Pharmaceuticals Industries (Sun Pharma) posted results lower than our expectations on the sales and net profit fronts, while the OPM came in higher than our expectations. Sales during the quarter came in at Rs3,927cr (V/s an expected Rs4,200cr), a yoy growth of 12.8%. On the operating front, the EBITDA margin stood at 43.9%, same as in 1QFY2014 and V/s an expected 41.8%). The adjusted net profit came in at Rs1,390cr, up 10.2% yoy. We remain Neutral on the stock.” “For 1QFY2015, the company posted results lower than our expectations on the sales and net profit fronts, while the OPM came in higher than our expectations. Sales during the quarter came in at Rs3,927cr, a yoy growth of 12.8% and V/s our expectations of Rs4,200cr. Branded generic sales in India, at Rs992cr, were up by 17% yoy over the corresponding period of last year. US finished dosage sales at US$389mn grew by 7% yoy. US sales were impacted mainly by a protection charge of US$79mn, taken by Taro during the quarter. International formulation sales outside US, at US$82mn, grew by 2% (in US$ terms) over the corresponding quarter of last year. The EBITDA margin, at 43.9%, was same as 1QFY2014 and V/s an expected 41.8%. The adjusted net profit came in at Rs1,390cr, a growth of 10.2% yoy and V/s an expected Rs1,428cr. The reported net profit was lower than expected in spite of a higher-than-expected OPM, due to higher taxation and lower than expected sales during the period.” “Sun Pharma is one of the largest and fastest growing Indian pharmaceutical companies. We expect its net sales to post a 25.4% CAGR (including Ranbaxy Laboratories) to Rs 38,186cr and EPS to post a 5.3% CAGR to Rs 32.1 over FY2014–16. We remain Neutral on the stock,” says Angel Broking research report.    

For all recommendations, click here 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More